Tivic Health CEO Jennifer Ernst resigns; Michael Handley appointed CEO to lead biopharma pivot

Valion Bio, Inc.

CEO Jennifer Ernst resigned March 2, 2026; board departure effective March 5; separation includes $325K cash severance, COBRA, equity vesting, and $50K restricted stock.
Michael Handley appointed CEO and board member effective March 3; previously COO and President of Tivic Biopharma since February 2025.
Handley brings over 20 years life sciences experience; led commercialization of 17 products, worked at Amgen and Genentech.
Company shifts strategic focus to late-stage immunotherapies and biomanufacturing subsidiary Velocity Bioworks; highlights Entolimod as key asset.
No dispute or disagreement with Ernst's resignation; Handley's existing employment agreement unchanged from February 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.